A Look at Novel Approaches in Bone Mets
Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies.
Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies. A recent study (Clin Cancer Res 2010 Aug 3) from the Massachusetts General Hospital Cancer Center, looked at studies optimizing bisphosphonate use and recent clinical data on denosumab in the treatment of bone disease. The study also provided insight into the preclinical rationale and clinical assessment of novel antiresorptive and anabolic bone-targeted agents.
Details available at:Novel Bone-Targeted Strategies in OncologyRelated content:Denosumab protects bones better than zoledronic acid in metastatic diseaseThe Role of Bisphosphonates in the Adjuvant Setting for Breast Cancer
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
